Powered by: Motilal Oswal

News

Stock of the day : Lupin Ltd For Target Rs. 2220 - Motilal Oswal Wealth Management Lupin Ltd Buy Lupin Ltd CMP 2099 SL 2038 Target 2220 Duration : 2-3 Days   For More Motilal Oswal Securities Ltd Disclaimer http://www.motilaloswal.com/MOSLdisclaimer/disclaimer.html SEBI Registration number is INH000000412
Stock of the day : Lupin Ltd For Target Rs. 2220 - Motilal Oswal Wealth Management
Stock of the day : Lupin Ltd For Target Rs. 2220 - Motilal Oswal Wealth Management
Source: Motilal Oswal Wealth Management
2024-12-19 12:01:49 pm
Lupin moves up on getting USFDA`s nod for Emtricitabine and Tenofovir Alafenamide Tablets Lupin is currently trading at Rs. 2116.45, up by 17.75 points or 0.85% from its previous closing of Rs. 2098.70 on the BSE. The scrip opened at Rs. 2098.05 and has touched a high and low of Rs. 2126.85 and Rs. 2080.10 respectively. So far 15741 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 2312.00 on 05-Sep-2024 and a 52 week low of Rs. 1200.35 on 21-Dec-2023. Last one week high and low of the scrip stood at R...
Lupin moves up on getting USFDA`s nod for Emtricitabine and Tenofovir Alafenamide Tablets
Lupin moves up on getting USFDA`s nod for Emtricitabine and Tenofovir Alafenamide Tablets
Source: Accord Fintech
2024-12-19 11:47:25 am
Neutral Lupin Ltd For Target Rs.2,210 By Motilal Oswal Financial Services Ltd India, EU, and growth markets drive earnings Building a respiratory, injectable, and GLP-1 pipeline * Lupin (LPC) delivered better-than-expected 2QFY25 performance. The beat was fueled by improved India business (the tender component), robust execution in the EU market, and lower raw material costs. However, the healthy performance was partly offset by higher R&D spending (up 60bp YoY as a % of sales) and higher employee costs. * We raise our earnings estimates by 15%/8%/7% for F...
Neutral Lupin Ltd For Target Rs.2,210 By Motilal Oswal Financial Services Ltd
Neutral Lupin Ltd For Target Rs.2,210 By Motilal Oswal Financial Services Ltd
Source: Motilal Oswal Financial Services
2024-12-01 09:47:27 am
Hold Lupin Ltd For Target Rs. 2,383 By Choice Broking Ltd Lupin reported revenue at INR 56,727mn increased by 12.6% YoY and 1.3% QoQ, driven by strong performance in India formulation business and 40% of US revenue coming from the complex generics. EBITDA at INR 13,083mn showed robust growth of 41.7% YoY and 1.7% QoQ, with a margin of 23.6%, expanding by 541bps YoY and 147bps QoQ. The improvement in EBITDA margin was driven by the change in the product mix and cost of raw material procurement coming down. Adj. PAT at INR 8,526mn saw a significant im...
Hold Lupin Ltd For Target Rs. 2,383 By Choice Broking Ltd
Hold Lupin Ltd For Target Rs. 2,383 By Choice Broking Ltd
Source: Choice Broking
2024-11-12 03:08:30 pm
Lupin inches up on reporting 74% rise in Q2 consolidated net profit Lupin is currently trading at Rs. 2110.75, up by 0.20 points or 0.01% from its previous closing of Rs. 2110.55 on the BSE. The scrip opened at Rs. 2144.00 and has touched a high and low of Rs. 2154.00 and Rs. 2080.00 respectively. So far 115331 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 2312.00 on 05-Sep-2024 and a 52 week low of Rs. 1153.55 on 13-Nov-2023. Last one week high and low of the scrip stood at R...
Lupin inches up on reporting 74% rise in Q2 consolidated net profit
Lupin inches up on reporting 74% rise in Q2 consolidated net profit
Source: Accord Fintech
2024-11-08 04:19:41 pm
Stock Picks : HDFC Life Insurance Company Ltd and Lupin Ltd By ICICI Direct HDFC Life Insurance Company Ltd Buy HDFC Life Insurance Company Ltd @ 724-726 Target 733.50 Stop Loss 720.40   Lupin Ltd Buy Lupin Ltd @ 2090-2094 Target 2073.00 Stop Loss 2104.50   Please refer disclaimer at https://secure.icicidirect.com/Content/StaticData/Disclaimer.html SEBI Registration number INZ000183631
Stock Picks : HDFC Life Insurance Company Ltd and Lupin Ltd By ICICI Direct
Stock Picks : HDFC Life Insurance Company Ltd and Lupin Ltd By ICICI Direct
Source: HDFC Securities
2024-10-24 10:39:42 am
Lupin inches up on launching first generic version of Pred Forte in United States Lupin is currently trading at Rs. 2248.00, up by 4.85 points or 0.22% from its previous closing of Rs. 2243.15 on the BSE. The scrip opened at Rs. 2234.15 and has touched a high and low of Rs. 2272.15 and Rs. 2234.15 respectively. So far 11302 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 2312.00 on 05-Sep-2024 and a 52 week low of Rs. 1113.00 on 31-Oct-2023. Last one week high and low of the scrip stood at Rs...
Lupin inches up on launching first generic version of Pred Forte in United States
Lupin inches up on launching first generic version of Pred Forte in United States
Source: Accord Fintech
2024-10-15 02:48:21 pm
Stock Picks : HDFC Bank Ltd And Lupin Ltd By ICICI Direct HDFC Bank Ltd Buy HDFC Bank Ltd @ 1635-1637 Target 1654.00 Stop Loss 1628.20   Lupin Ltd Buy Lupin Ltd @ 2287-2289 Target 2312.00 Stop Loss 2276.40   Please refer disclaimer at https://secure.icicidirect.com/Content/StaticData/Disclaimer.html SEBI Registration number INZ000183631
Stock Picks : HDFC Bank Ltd And Lupin Ltd By ICICI Direct
Stock Picks : HDFC Bank Ltd And Lupin Ltd By ICICI Direct
Source: ICICI Direct
2024-10-10 12:08:43 pm
Lupin surges on inking distribution pact with Scope Ophthalmics Lupin is currently trading at Rs. 2193.05, up by 2.85 points or 0.13% from its previous closing of Rs. 2190.20 on the BSE. The scrip opened at Rs. 2186.45 and has touched a high and low of Rs. 2207.65 and Rs. 2175.25 respectively. So far 9505 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 2312.00 on 05-Sep-2024 and a 52 week low of Rs. 1113.00 on 31-Oct-2023. Last one week high and low of the scrip stood at Rs....
Lupin surges on inking distribution pact with Scope Ophthalmics
Lupin surges on inking distribution pact with Scope Ophthalmics
Source: Accord Fintech
2024-10-01 02:36:07 pm
Saksoft, HDFC Life and Tata Motors to see some action today Saksoft has acquired Ceptes Software, a recognized expert in Salesforce services, headquartered in Bengaluru, Karnataka. The company anticipates the transaction will be closed within 4 weeks pending customary closing conditions. This strategic acquisition will significantly help Saksoft expand its capabilities around Salesforce solutions, cloud innovation, and customer experience optimization.  HDFC Life Insurance Company has received approval to raise funds up to Rs 1,500 c...
Saksoft, HDFC Life and Tata Motors to see some action today
Saksoft, HDFC Life and Tata Motors to see some action today
Source: Accord Fintech
2024-09-30 08:57:05 am
Lupin zooms on launching Mirabegron Extended-Release Tablets in United States Lupin is currently trading at Rs. 2274.10, up by 35.00 points or 1.56% from its previous closing of Rs. 2239.10 on the BSE. The scrip opened at Rs. 2220.75 and has touched a high and low of Rs. 2286.25 and Rs. 2205.25 respectively. So far 17884 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 2,286.25 on 04-Sep-2024 and a 52 week low of Rs. 1091.80 on 22-Sep-2023. Last one week high and low of the scrip stood at ...
Lupin zooms on launching Mirabegron Extended-Release Tablets in United States
Lupin zooms on launching Mirabegron Extended-Release Tablets in United States
Source: Accord Fintech
2024-09-04 04:35:55 pm
Neutral Lupin Ltd For Target Rs. 2,050 By Motilal Oswal Financial Services Ltd Maintains high-single digit YoY growth guidance for US generics (FY25) * LPC delivered a strong earnings beat in 1QFY25, led by a superior show in key markets (US/India), lower R&D spending and a low tax rate. LPC posted the highest quarterly EBITDA margin in five years. *  We raise our earnings estimates by 17% each for FY25/FY26, factoring in a) a niche product pipeline for US generics market, b) improved traction in API segment, c) benefits from PLI scheme, d) reduced prices...
Neutral Lupin Ltd For Target Rs. 2,050 By Motilal Oswal Financial Services Ltd
Neutral Lupin Ltd For Target Rs. 2,050 By Motilal Oswal Financial Services Ltd
Source: Motilal Oswal Financial Services Ltd
2024-08-24 09:20:06 am
Buy Lupin Ltd For Target Rs.2,237 By Choice Broking Ltd Lupin reported earnings above our estimates across all metrics. Revenue at INR 55,143 mn increased by 16.3% YoY and 12.6% QoQ, driven by strong performance in North America, Growth, and Emerging markets. EBITDA at INR 12,409 mn showed robust growth of 44.9% YoY and 24.5% QoQ, with a margin of 22.5%, expanding 445bps YoY and 214bps QoQ. The improvement in EBITDA margin was driven by strong commercial execution of new product launches, solid performance of existing products, and lower than anti...
Buy Lupin Ltd For Target Rs.2,237 By Choice Broking Ltd
Buy Lupin Ltd For Target Rs.2,237 By Choice Broking Ltd
Source: Choice Broking
2024-08-10 10:26:31 am
Lupin jumps after its arm incorporates wholly owned subsidiary in New Zealand Lupin is currently trading at Rs. 2062.00, up by 69.30 points or 3.48% from its previous closing of Rs. 1992.70 on the BSE. The scrip opened at Rs. 2014.00 and has touched a high and low of Rs. 2066.30 and Rs. 2004.00 respectively. So far 72851 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 2066.30 on 08-Aug-2024 and a 52 week low of Rs. 1061.25 on 21-Aug-2023. Last one week high and low of the scrip stood at R...
Lupin jumps after its arm incorporates wholly owned subsidiary in New Zealand
Lupin jumps after its arm incorporates wholly owned subsidiary in New Zealand
Source: Accord Fintech
2024-08-08 04:16:16 pm
Lupin zooms on reporting strong Q1 numbers; consolidated net profit jumps 78% Lupin is currently trading at Rs. 2007.35, up by 100.35 points or 5.26% from its previous closing of Rs. 1907.00 on the BSE. The scrip opened at Rs. 2011.00 and has touched a high and low of Rs. 2025.00 and Rs. 1953.00 respectively. So far 77613 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 2,025.00 on 07-Aug-2024 and a 52 week low of Rs. 1,061.25 on 21-Aug-2023. Last one week high and low of the scrip stood a...
Lupin zooms on reporting strong Q1 numbers; consolidated net profit jumps 78%
Lupin zooms on reporting strong Q1 numbers; consolidated net profit jumps 78%
Source: Accord Fintech
2024-08-07 11:27:43 am
Stock of the day : Lupin Ltd. For Target Rs.1715 - Religare Broking Lupin Ltd. * Pharma index has rebounded from the key support zone and LUPIN is offering fresh buying opportunity with favorable Risk to Reward. * The stock has managed to hold its key demand zone and have rebounded strongly with decent volumes. * It has recorded a breakout from falling resistance trendline and have reclaimed its short term moving average i.e. 20 DEMA. * Traders can consider fresh longs in the mentioned range.   BUY Lupin Ltd. CMP 1621...
Stock of the day : Lupin Ltd. For Target Rs.1715 - Religare Broking
Stock of the day : Lupin Ltd. For Target Rs.1715 - Religare Broking
Source: Religare Broking
2024-07-01 11:00:56 am
Lupin surges as its arm completes acquisition of two brands from Sanofi in Europe, Canada Lupin is currently trading at Rs. 1640.60, up by 77.35 points or 4.95% from its previous closing of Rs. 1563.25 on the BSE. The scrip opened at Rs. 1582.70 and has touched a high and low of Rs. 1640.95 and Rs. 1572.25 respectively. So far 14819 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1727.90 on 22-May-2024 and a 52 week low of Rs. 805.40 on 09-Jun-2023. Last one week high and low of the scrip stood at Rs...
Lupin surges as its arm completes acquisition of two brands from Sanofi in Europe, Canada
Lupin surges as its arm completes acquisition of two brands from Sanofi in Europe, Canada
Source: Accord Fintech
2024-06-05 02:16:05 pm
Accumulate Lupin for Target Rs 1,820 by Elara Capital Going strong, but profit concentration risk Strong beat in Q4FY24 Lupin’s(LPC IN) Q4 results were well ahead of our expectations – Revenue came 2% below, but better margins led to EBITDA and PAT (adjusted for one-time impairment of intangible assets) beating our estimates by 10% and 27%, respectively. We believe that the margin upside came mostly from better product mix in the US, from higher contribution from gSpiriva. We estimate ~USD 40mn high-margin gSpiriva sales in the qu...
Accumulate Lupin for Target Rs 1,820 by Elara Capital
Accumulate Lupin for Target Rs 1,820 by Elara Capital
Source: Elara Capital
2024-06-04 04:38:50 pm
Neutral Lupin Ltd. For Traget Rs.1,550 - Motilal Oswal Financial Services Work-in-progress to further build product pipeline in key markets -      Lupin (LPC) delivered in-line operational performance in 4QFY24. LPC ended FY24 on a strong note, with INR198b in sales (up 19% YoY), EBITDA margin of 18% (up 750bp YoY) and PAT of INR19b (vs. INR4b YoY). LPC continues to implement efforts toward building a complex product pipeline in inhalation, injectables and ophthalmics. -      We raise our e...
Neutral Lupin Ltd. For Traget Rs.1,550 - Motilal Oswal Financial Services
Neutral Lupin Ltd. For Traget Rs.1,550 - Motilal Oswal Financial Services
Source: Motilal Oswal Financial Services Ltd
2024-06-04 10:27:27 am
Lupin falls despite reporting 52% rise in Q4 consolidated net profit Lupin is currently trading at Rs. 1605.95, down by 73.80 points or 4.39% from its previous closing of Rs. 1679.75 on the BSE. The scrip opened at Rs. 1686.70 and has touched a high and low of Rs. 1686.70 and Rs. 1561.00 respectively. So far 149632 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1703.80 on 11-Mar-2024 and a 52 week low of Rs. 704.05 on 08-May-2023. Last one week high and low of the scrip stood at...
Lupin falls despite reporting 52% rise in Q4 consolidated net profit
Lupin falls despite reporting 52% rise in Q4 consolidated net profit
Source: Accord Fintech
2024-05-07 03:18:10 pm
Lupin rises on the BSE Lupin is currently trading at Rs. 1595.15, up by 14.60 points or 0.92% from its previous closing of Rs. 1580.55 on the BSE.  The scrip opened at Rs. 1595.00 and has touched a high and low of Rs. 1602.50 and Rs. 1588.15 respectively. So far 7418 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1703.80 on 11-Mar-2024 and a 52 week low of Rs. 680.35 on 27-Apr-2023. Last one week high and low of the scrip stood ...
Lupin rises on the BSE
Lupin rises on the BSE
Source: Accord Fintech
2024-04-24 10:26:45 am
Lupin jumps on launching Mirabegron Extended-Release tablets Lupin is currently trading at Rs. 1594.85, up by 47.80 points or 3.09% from its previous closing of Rs. 1547.05 on the BSE. The scrip opened at Rs. 1599.50 and has touched a high and low of Rs. 1603.00 and Rs. 1570.35 respectively. So far 14575 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1703.80 on 11-Mar-2024 and a 52 week low of Rs. 678.90 on 20-Apr-2023. Last one week high and low of the scrip stood at Rs...
Lupin jumps on launching Mirabegron Extended-Release tablets
Lupin jumps on launching Mirabegron Extended-Release tablets
Source: Accord Fintech
2024-04-22 10:34:56 am
Lupin rises on launching first generic version of Oracea in United States Lupin is currently trading at Rs. 1627.95, up by 22.90 points or 1.43% from its previous closing of Rs. 1605.05 on the BSE. The scrip opened at Rs. 1633.25 and has touched a high and low of Rs. 1644.20 and Rs. 1625.00 respectively. So far 7867 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1703.80 on 11-Mar-2024 and a 52 week low of Rs. 655.75 on 17-Apr-2023. Last one week high and low of the scrip stood at Rs....
Lupin rises on launching first generic version of Oracea in United States
Lupin rises on launching first generic version of Oracea in United States
Source: Accord Fintech
2024-04-10 09:34:28 am
Accumulate Lupin Ltd For Target Rs. 1,820 - Elara Capital gSpiriva sees quick ramp-up Strong beat in Q3FY24 Lupin’s (LPC IN) Q3 results were well ahead of our expectations – Revenue, EBITDA and PAT beat our estimates by 7%, 41% and 92%, respectively. The upside came in mostly from faster ramp-up in gSpiriva product in the US, but also supported by stronger growth in most other geographies. We estimate ~USD 25mn high-margin gSpiriva sales in Q3. US generics – Momen...
Accumulate Lupin Ltd For Target Rs. 1,820 - Elara Capital
Accumulate Lupin Ltd For Target Rs. 1,820 - Elara Capital
Source: Elara Capital
2024-03-08 09:30:30 am
Exclusive-Eli Lilly could launch obesity drug in India next year, CEO says U.S. drugmaker Eli Lilly expects to launch Mounjaro, its blockbuster diabetes drug and wildly popular obesity treatment, in India as early as next year after it clears an ongoing regulatory review, CEO David Ricks told Reuters on Wednesday. The market opportunity is huge in the world's most populous country, which has high obesity rates, especially among women, and the second-highest number of people with type-2 diabetes globally. Indian drugmakers are making their own versions of such...
Exclusive-Eli Lilly could launch obesity drug in India next year, CEO says
Exclusive-Eli Lilly could launch obesity drug in India next year, CEO says
Source: Reuters
2024-02-28 05:09:26 pm
India pharma companies develop versions of Wegovy to get in on weight-loss windfall  Indian drugmakers aiming to grab a slice of the burgeoning weight-loss treatment sales pie, both at home and abroad, have begun developing their own versions of Novo Nordisk's wildly in demand Wegovy. With some analysts predicting a weight-loss market reaching $100 billion a year or more by the end of the decade, executives at Sun Pharma, Cipla, Dr Reddy's and Lupin -- some of the world's largest generic drugmakers -- all said they have started work on Wegovy versions. ...
India pharma companies develop versions of Wegovy to get in on weight-loss windfall
India pharma companies develop versions of Wegovy to get in on weight-loss windfall
Source: Reuters
2024-02-22 12:03:24 pm
Lupin jumps on receiving USFDA`s approval for Minzoya tablets Lupin is currently trading at Rs. 1625.30, up by 20.15 points or 1.26% from its previous closing of Rs. 1605.15 on the BSE. The scrip opened at Rs. 1608.00 and has touched a high and low of Rs. 1638.00 and Rs. 1598.15 respectively. So far 35953 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1701.00 on 08-Feb-2024 and a 52 week low of Rs. 628.10 on 31-Mar-2023. Last one week high and low of the scrip stood at Rs...
Lupin jumps on receiving USFDA`s approval for Minzoya tablets
Lupin jumps on receiving USFDA`s approval for Minzoya tablets
Source: Accord Fintech
2024-02-16 03:16:50 pm
Lupin trades higher on BSE Lupin is currently trading at Rs. 1624.35, up by 18.25 points or 1.14% from its previous closing of Rs. 1606.10 on the BSE. The scrip opened at Rs. 1619.75 and has touched a high and low of Rs. 1654.00 and Rs. 1615.60 respectively. So far 23086 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1701.00 on 08-Feb-2024 and a 52 week low of Rs. 628.10 on 31-Mar-2023. Last one week high and low of the scrip stood at Rs...
Lupin trades higher on BSE
Lupin trades higher on BSE
Source: Accord Fintech
2024-02-09 10:28:56 am
Outperform Lupin Ltd for Target Rs. 1,873 - Choice broking Lupin's reported earnings slightly surpassed our projections, driven by robust performance in major markets and effective operational efficiency. The company posted a top-line of INR 51,974mn, indicating a substantial 20.2% YoY increase and a modest 3.2% QoQ growth, primarily fueled by strong growth in North America, EMEA, and RoW. In Q3FY24, EBITDA reached INR 10,220mn, marking an impressive 98% YoY surge and a noteworthy 10.7% QoQ uptick. The EBITDA margin at 20%, demonstrated improveme...
Outperform Lupin Ltd for Target Rs. 1,873 - Choice broking
Outperform Lupin Ltd for Target Rs. 1,873 - Choice broking
Source: Choice Broking
2024-02-09 10:23:39 am
Lupin surges on reporting around 4-fold jump in Q3 consolidated net profit Lupin is currently trading at Rs. 1632.75, up by 37.10 points or 2.33% from its previous closing of Rs. 1595.65 on the BSE. The scrip opened at Rs. 1700.00 and has touched a high and low of Rs. 1701.00 and Rs. 1617.50 respectively. So far 104710 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1701.00 on 08-Feb-2024 and a 52 week low of Rs. 628.10 on 31-Mar-2023. Last one week high and low of the scrip stood at R...
Lupin surges on reporting around 4-fold jump in Q3 consolidated net profit
Lupin surges on reporting around 4-fold jump in Q3 consolidated net profit
Source: Accord Fintech
2024-02-08 11:51:04 am
Lupin moves up on receiving USFDA`s approval for Bromfenac Ophthalmic Solution Lupin is currently trading at Rs. 1584.70, up by 4.95 points or 0.31% from its previous closing of Rs. 1579.75 on the BSE. The scrip opened at Rs. 1600.00 and has touched a high and low of Rs. 1605.00 and Rs. 1577.55 respectively. So far 16787 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1605.00 on 07-Feb-2024 and a 52 week low of Rs. 628.10 on 31-Mar-2023. Last one week high and low of the scrip stood at Rs....
Lupin moves up on receiving USFDA`s approval for Bromfenac Ophthalmic Solution
Lupin moves up on receiving USFDA`s approval for Bromfenac Ophthalmic Solution
Source: Accord Fintech
2024-02-07 11:35:23 am
Lupin rises on getting tentative nod for Rivaroxaban Tablets Lupin is currently trading at Rs. 1455.80, up by 15.50 points or 1.08% from its previous closing of Rs. 1440.30 on the BSE. The scrip opened at Rs. 1449.75 and has touched a high and low of Rs. 1461.50 and Rs. 1434.65 respectively. So far 18756 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1,461.50 on 24-Jan-2024 and a 52 week low of Rs. 628.10 on 31-Mar-2023. Last one week high and low of the scrip stood at R...
Lupin rises on getting tentative nod for Rivaroxaban Tablets
Lupin rises on getting tentative nod for Rivaroxaban Tablets
Source: Accord Fintech
2024-01-24 10:56:49 am
Lupin jumps on getting nod for Propranolol Hydrochloride Extended-Release Capsules Lupin is currently trading at Rs. 1417.95, up by 19.50 points or 1.39% from its previous closing of Rs. 1398.45 on the BSE. The scrip opened at Rs. 1419.50 and has touched a high and low of Rs. 1423.15 and Rs. 1397.75 respectively. So far 20774 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1429.95 on 05-Jan-2024 and a 52 week low of Rs. 628.10 on 31-Mar-2023. Last one week high and low of the scrip stood at Rs...
Lupin jumps on getting nod for Propranolol Hydrochloride Extended-Release Capsules
Lupin jumps on getting nod for Propranolol Hydrochloride Extended-Release Capsules
Source: Accord Fintech
2024-01-15 01:00:58 pm
Lupin rises on launching Varenicline Tablets Lupin is currently trading at Rs. 1411.50, up by 6.35 points or 0.45% from its previous closing of Rs. 1405.15 on the BSE. The scrip opened at Rs. 1405.00 and has touched a high and low of Rs. 1417.65 and Rs. 1405.00 respectively. So far 7085 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1429.95 on 05-Jan-2024 and a 52 week low of Rs. 628.10 on 31-Mar-2023. Last one week high and low of the scrip stood at Rs. ...
Lupin rises on launching Varenicline Tablets
Lupin rises on launching Varenicline Tablets
Source: Accord Fintech
2024-01-11 12:10:47 pm
Lupin inches up on launching Bromfenac Ophthalmic Solution Lupin is currently trading at Rs. 1398.40, up by 2.35 points or 0.17% from its previous closing of Rs. 1396.05 on the BSE. The scrip opened at Rs. 1412.50 and has touched a high and low of Rs. 1414.95 and Rs. 1396.05 respectively. So far 5710 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1429.95 on 05-Jan-2024 and a 52 week low of Rs. 628.10 on 31-Mar-2023. Last one week high and low of the scrip stood at Rs. ...
Lupin inches up on launching Bromfenac Ophthalmic Solution
Lupin inches up on launching Bromfenac Ophthalmic Solution
Source: Accord Fintech
2024-01-10 09:45:27 am
Lupin inches up on getting USFDA`s tentative approval for Dapagliflozin and Saxagliptin Tablets Lupin is currently trading at Rs. 1402.35, up by 4.45 points or 0.32% from its previous closing of Rs. 1397.90 on the BSE. The scrip opened at Rs. 1429.95 and has touched a high and low of Rs. 1429.95 and Rs. 1399.35 respectively. So far 16984 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1,429.95 on 05-Jan-2024 and a 52 week low of Rs. 628.10 on 31-Mar-2023. Last one week high and low of the scrip stood at Rs...
Lupin inches up on getting USFDA`s tentative approval for Dapagliflozin and Saxagliptin Tablets
Lupin inches up on getting USFDA`s tentative approval for Dapagliflozin and Saxagliptin Tablets
Source: Accord Fintech
2024-01-05 09:59:58 am
Stock Picks : Gail (India) Limited And Lupin Ltd By ICICI Direct Gail (India) Limited Buy Gail (India) Limited @156.50-157.00; Target 158.90; Stop Loss 155.80   Lupin Limited Buy Lupin Limited @1338-1340; Target 1354.00; Stop Loss 1331.80   Please refer disclaimer at https://secure.icicidirect.com/Content/StaticData/Disclaimer.html SEBI Registration number INZ000183631
Stock Picks : Gail (India) Limited And Lupin Ltd By ICICI Direct
Stock Picks : Gail (India) Limited And Lupin Ltd By ICICI Direct
Source: ICICI Direct
2023-12-29 10:54:39 am
Lupin gains on receiving USFDA`s approval for Loteprednol Etabonate Ophthalmic Suspension Lupin is currently trading at Rs. 1301.00, up by 12.00 points or 0.93% from its previous closing of Rs. 1289.00 on the BSE. The scrip opened at Rs. 1289.15 and has touched a high and low of Rs. 1311.35 and Rs. 1289.15 respectively. So far 22525 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1319.90 on 04-Dec-2023 and a 52 week low of Rs. 628.10 on 31-Mar-2023. Last one week high and low of the scrip stood at Rs...
Lupin gains on receiving USFDA`s approval for Loteprednol Etabonate Ophthalmic Suspension
Lupin gains on receiving USFDA`s approval for Loteprednol Etabonate Ophthalmic Suspension
Source: Accord Fintech
2023-12-28 10:36:14 am
Lupin moves up on launching Softovac Liquifibre Lupin is currently trading at Rs. 1279.50, up by 23.95 points or 1.91% from its previous closing of Rs. 1255.55 on the BSE. The scrip opened at Rs. 1261.85 and has touched a high and low of Rs. 1283.60 and Rs. 1258.70 respectively. So far 11304 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1319.90 on 04-Dec-2023 and a 52 week low of Rs. 628.10 on 31-Mar-2023. Last one week high and low of the scrip stood at Rs...
Lupin moves up on launching Softovac Liquifibre
Lupin moves up on launching Softovac Liquifibre
Source: Accord Fintech
2023-12-22 10:34:55 am
Lupin inches up on receiving approval from USFDA for Varenicline Tablets Lupin is currently trading at Rs. 1263.65, up by 4.95 points or 0.39% from its previous closing of Rs. 1258.70 on the BSE. The scrip opened at Rs. 1260.45 and has touched a high and low of Rs. 1266.00 and Rs. 1254.65 respectively. So far 8622 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1319.90 on 04-Dec-2023 and a 52 week low of Rs. 628.10 on 31-Mar-2023. Last one week high and low of the scrip stood at Rs. ...
Lupin inches up on receiving approval from USFDA for Varenicline Tablets
Lupin inches up on receiving approval from USFDA for Varenicline Tablets
Source: Accord Fintech
2023-12-06 10:21:53 am
Stock Picks : Lupin Ltd And Indian Hotel Ltd By ICICI Direct Lupin Ltd Buy Lupin Ltd @1242-1243; Target 1255.00; Stop Loss 1236.40   Indian Hotel Ltd Buy Indian Hotel Ltd @419-421; Target 426.00; Stop Loss 417.30   Please refer disclaimer at https://secure.icicidirect.com/Content/StaticData/Disclaimer.html SEBI Registration number INZ000183631
Stock Picks : Lupin Ltd And Indian Hotel Ltd By ICICI Direct
Stock Picks : Lupin Ltd And Indian Hotel Ltd By ICICI Direct
Source: ICICI Direct
2023-11-28 10:15:35 am
Lupin shines on getting USFDA`s tentative nod for Canagliflozin Tablets Lupin is currently trading at Rs. 1217.75, up by 21.45 points or 1.79% from its previous closing of Rs. 1196.30 on the BSE. The scrip opened at Rs. 1223.95 and has touched a high and low of Rs. 1233.40 and Rs. 1213.20 respectively. So far 35427 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1239.90 on 22-Nov-2023 and a 52 week low of Rs. 628.10 on 31-Mar-2023. Last one week high and low of the scrip stood at Rs...
Lupin shines on getting USFDA`s tentative nod for Canagliflozin Tablets
Lupin shines on getting USFDA`s tentative nod for Canagliflozin Tablets
Source: Accord Fintech
2023-11-24 10:38:45 am
Lupin gains on getting USFDA`s approval for Pitavastatin Tablets Lupin is currently trading at Rs. 1231.00, up by 8.55 points or 0.70% from its previous closing of Rs. 1222.45 on the BSE. The scrip opened at Rs. 1222.00 and has touched a high and low of Rs. 1239.90 and Rs. 1219.80 respectively. So far 24899 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1239.90 on 22-Nov-2023 and a 52 week low of Rs. 628.10 on 31-Mar-2023. Last one week high and low of the scrip stood at Rs....
Lupin gains on getting USFDA`s approval for Pitavastatin Tablets
Lupin gains on getting USFDA`s approval for Pitavastatin Tablets
Source: Accord Fintech
2023-11-22 02:27:37 pm
Outperform Lupin Ltd For Target Rs. 1451 - Choice Broking Lupin's reported earnings were slightly above our estimates on the revenue and margin front, which was driven by strong momentum across major geographies and achieving operating leverage. Lupin reported a top-line of INR 50,386mn (up 4.7% QoQ and 21.5% YoY), driven by strong growth in North America, Emerging markets, and India. Q2FY24 EBITDA at INR 9,231mn (up 7.8% QoQ and 112.6% YoY) and margin at 18.2%, improved due to managing costs and achieving operating leverage. PAT at INR 4,897mn ...
Outperform Lupin Ltd For Target Rs. 1451 - Choice Broking
Outperform Lupin Ltd For Target Rs. 1451 - Choice Broking
Source: Choice Broking Ltd
2023-11-11 02:12:52 pm
Lupin gains on reporting over 3-fold jump in Q2 consolidated net profit Lupin is currently trading at Rs. 1231.90, up by 20.20 points or 1.67% from its previous closing of Rs. 1211.70 on the BSE. The scrip opened at Rs. 1222.05 and has touched a high and low of Rs. 1235.65 and Rs. 1204.25 respectively. So far 88844 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1,235.65 on 09-Nov-2023 and a 52 week low of Rs. 628.10 on 31-Mar-2023. Last one week high and low of the scrip stood at R...
Lupin gains on reporting over 3-fold jump in Q2 consolidated net profit
Lupin gains on reporting over 3-fold jump in Q2 consolidated net profit
Source: Accord Fintech
2023-11-09 12:08:06 pm
Lupin rises on getting USFDA`s tentative nod for Canagliflozin, Metformin Hydrochloride Extended-Release Tablets Lupin The scrip is currently trading at Rs. 1203.95, up by 14.75 points or 1.24% from its previous closing of Rs. 1189.20 on the BSE. The scrip opened at Rs. 1211.90 and has touched a high and low of Rs. 1211.90 and Rs. 1198.35 respectively. So far 2492 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1215.20 on 17-Oct-2023 and a 52 week low of Rs. 628.10 on 31-Mar-2023. Last one week high and low of the scrip st...
Lupin rises on getting USFDA`s tentative nod for Canagliflozin, Metformin Hydrochloride Extended-Release Tablets
Lupin rises on getting USFDA`s tentative nod for Canagliflozin, Metformin Hydrochloride Extended-Release Tablets
Source: Accord Fintech
2023-11-08 11:22:58 am
Lupin shines on launching Diazepam Rectal Gel in United States Lupin is currently trading at Rs. 1191.90, up by 22.55 points or 1.93% from its previous closing of Rs. 1169.35 on the BSE. The scrip opened at Rs. 1173.75 and has touched a high and low of Rs. 1201.00 and Rs. 1173.75 respectively. So far 14158 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1215.20 on 17-Oct-2023 and a 52 week low of Rs. 628.10 on 31-Mar-2023. Last one week high and low of the scrip stood at Rs...
Lupin shines on launching Diazepam Rectal Gel in United States
Lupin shines on launching Diazepam Rectal Gel in United States
Source: Reuters
2023-11-03 10:19:22 am
Lupin zooms on receiving USFDA`s approval for Selexipag for Injection Lupin is currently trading at Rs. 1177.45, up by 44.90 points or 3.96% from its previous closing of Rs. 1132.55 on the BSE. The scrip opened at Rs. 1139.90 and has touched a high and low of Rs. 1183.85 and Rs. 1135.00 respectively. So far 211055 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1215.20 on 17-Oct-2023 and a 52 week low of Rs. 628.10 on 31-Mar-2023. Last one week high and low of the scrip stood at R...
Lupin zooms on receiving USFDA`s approval for Selexipag for Injection
Lupin zooms on receiving USFDA`s approval for Selexipag for Injection
Source: Accord Fintech
2023-11-02 02:07:19 pm